Archive for November, 2020

$WRTC to Begin Trading Under Nasdaq Ticker Symbol “WRAP”

Wrap Technologies (NASDAQ: WRTC), an innovator of modern policing solutions, today announced that its Nasdaq ticker symbol is set to change from “WRTC” to “WRAP” beginning at market open on Tuesday, December 1, 2020. “We are excited to align the new ticker symbol ‘WRAP’ directly to our corporate brand and strengthen our visibility with public investors while providing consistent brand recognition across all stakeholders,” Wrap Technologies President and Interim CEO Tom Smith stated in the news release. “We are protecting our WRAP(R) and BolaWrap(R) brands in 50 countries as our brand recognition continues to increase worldwide. The recent change of our corporate web site to ‘wrap.com’ along with the new ticker symbol makes it easier for customers, current shareholders and prospective investors to find and follow our company.”

To view the full press release, visit https://ibn.fm/orTFk

About Wrap Technologies Inc.

WRAP Technologies, Inc. is an innovator of modern policing solutions. The company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar(R) tether to restrain an individual at a distance from 10 to 25 feet. Developed by award winning inventor Elwood Norris, the Company’s Chief Technology Officer, the small but powerful BolaWrap 100 assists law enforcement in safely and effectively deescalating encounters, especially those involving an individual in crisis. BolaWrap 100 has already been used to safely apprehend suspects without injury in a number of cities including Los Angeles, Sacramento, Fresno, Bell, Albuquerque, Minneapolis, West Palm Beach, Fort Worth, and Oak Ridge. For information, visit the company’s website at www.WrapTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to WRTC are available in the company’s newsroom at http://ibn.fm/WRTC

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Monday, November 30th, 2020 Uncategorized Comments Off on $WRTC to Begin Trading Under Nasdaq Ticker Symbol “WRAP”

$VTGN Announces Positive Preclinical Data for Potential Anxiety Treatment

  • VTGN CEO “even more excited about PH94B’s potential to change lives without the risky side effects and safety concerns of benzos”
  • Study results suggest PH94B’s mechanism of action may not have benzodiazepine-like side effects, such as sedation, cognitive impairment or abuse liability
  • Company making significant progress in preparing PH94B for launch of pivotal Phase 3 study for acute treatment of anxiety in adults with social anxiety disorder

VistaGen Therapeutics (NASDAQ: VTGN) has reported new preclinical findings differentiating the mechanism of action of PH94B from that of benzodiazepines (https://ibn.fm/Al4ur). PH94B is an intranasal neuroactive steroid VistaGen is preparing for Phase 3 development as a potential acute rapid-onset treatment of anxiety in adults with social anxiety disorder. As a solution to anxiety notably lacking the notorious side effects of traditional medications, the formulation could be a game-changer to the world of mental health.

“We are very pleased with the results of these studies that suggest PH94B’s mechanism of action may not have benzodiazepine-like side effects, such as sedation and cognitive impairment, or abuse liability,” said VistaGen CEO Shawn K. Singh. “While benzodiazepines provide relief for many Americans struggling with anxiety, the extremely risky safety profile does not lend itself to long-term use. The mechanism of action contributes to the safety profile.”

VistaGen, a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, reported that new in vitro electrophysiology data demonstrating that PH94B’s mechanism of action does not involve direct activation of GABA-A receptors. That is in direct contrast to the mechanism of action of benzodiazepines (benzos), which act as direct positive modulators of GABA-A receptors.

“As we have seen in Phase 2 clinical studies, while PH94B is able to produce rapid-onset benzo-like, anti-anxiety effects, this study demonstrates that PH94B does not have a benzo-like mechanism of action,” noted Singh. “As we approach Phase 3 development of PH94B, especially given the FDA’s recent public announcement about safety concerns associated with benzo use, these new data make us even more excited about PH94B’s potential to change lives without the risky side effects and safety concerns of benzos.”

In additional news, VistaGen also provided business updates and released its financial results for the fiscal 2021 second quarter ended September 30, 2020 (https://ibn.fm/kBQkL). Key highlights for the company included a positive FDA meeting that outlined the pathway to a key PH94B Phase 3 study beginning recruitment Q2 2021, along with news that the company had received more than $17.5 million in net proceeds from a public offering of common stock and a PH94B upfront license payment. The company also noted positive new data had been gathered from its second preclinical study of AV-101 in combination with probenecid.

“We see a significant rise in mental health concerns as the global COVID-19 pandemic continues to impact the daily lives of millions of individuals,” observed Singh. “We are committed to developing innovative therapies that provide relief to those suffering from anxiety and depression, and we are working diligently towards that goal.

“We are making significant progress in preparing PH94B for launch of a pivotal Phase 3 study for acute treatment of anxiety in adults with social anxiety disorder in the second quarter of 2021,” he continued. “After reaching consensus with the FDA on the key components of the study design, it will be very similar to the statistically significant Phase 2 study of PH94B in social anxiety disorder. We are also working with the FDA to finalize details for our Phase 2A study of PH94B in adjustment disorder, which we are planning to initiate in early 2021.”

VistaGen is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen’s three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date and therapeutic potential in multiple CNS markets.

For more information, visit the company’s website at www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Monday, November 30th, 2020 Uncategorized Comments Off on $VTGN Announces Positive Preclinical Data for Potential Anxiety Treatment

$POAI Psychologist Explains Reason Behind Reckless Behavior Amid Worsening Pandemic

In the last month, COVID-19 cases have increased significantly in New Jersey and Pennsylvania. The recent numbers top the figures recorded during the first wave of the coronavirus when the pandemic first hit. The rising numbers isn’t the most puzzling factor about this; more puzzling may be the fact that, despite the rising cases, people continue to make plans to meet up with family and friends during the upcoming Thanksgiving holiday, instead of social distancing.

To help contain the contagion, officials in Philadelphia introduced restrictions last week that limited the number of people in outdoor gatherings and closed museums, gyms and indoor dining. Restrictions on capacity of people in gatherings was also introduced by Gov. Phil Murphy of New Jersey. The announcement noted that, before the restrictions came in effect, people carried on with their activities, including going to parties and dining out, a normal many had thought was left in a pre-corona world.

But why is it that some individuals thought it best to continue socializing even as the risk of contracting the coronavirus grew?

Assistant psychology professor Melissa Auerbach explains that after a long time of not being able to interact with people in a social setting, individuals grew tired, which allowed them to so easily disregard the growing coronavirus cases when it came to making decisions.

The Temple University professor has studied health risk behaviors and stress; she says that individuals possess fixed mental resources when it comes to self-control. The lack of socializing, the pandemic and the ongoing recession only aids in further depletion of self-control.

Auerbach states that individuals begin the descent into a downward spiral when they are restricted from interacting with others. This may cause people to go for that which conforms to their wants rather than that which is real. She adds that the weather may also have a hand in this behavior, given that both October and November are peak seasonal affective disorder months. This may prompt individuals to seek out their support systems to help them cope with stress or indulge in activities that help them decompress or relax.

Seeing a person in a position of power, such as the president of the United States, flouting the same guidelines that have been implemented to help prevent the spread of the virus may also encourage individuals to engage in these risky exploits.

Regardless, it should be noted that the idea that if you have not contracted the virus yet, you may be impregnable to it is absurd to say the least.

The coronavirus pandemic is certainly a recent challenge, but many biotech companies have been engaged in finding solutions to debilitating conditions that have existed for much long, including cancer. Predictive Oncology (NASDAQ: POAI), for example, is a company whose sole aim is to improve cancer diagnosis through the use of AI and data analytics.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Monday, November 30th, 2020 Uncategorized Comments Off on $POAI Psychologist Explains Reason Behind Reckless Behavior Amid Worsening Pandemic

$NETE As World Transitions away from Gas Guzzlers, Net Element Entering EV Market Through Mullen Technologies Merger

  • NETE plans to divest payments processing model to enter EV industry through proposed merger with privately-held Mullen Technologies Inc.
  • Merger allows Mullen stakeholders to obtain majority of stock while accelerating process of taking company public, funding US expansion
  • Mullen accepting reservations for Dragonfly K50 sports car and MX-05 SUV, production for both projected to start in 2021
  • California-based Mullen subsidiaries include Mullen Energy, Mullen Auto Sales, Mullen Finance Corp., CarHub digital marketplace

Future generations may look back and wonder how humanity withstood the exhaust fumes, noise and environmental degradation created by fossil fuel engines. The downsides of combustible engines, rising fuel prices and positive government incentives are all factors driving EVs into the mainstream – and some experts predict purely electric models will surpass hybrids during the transition. Net Element (NASDAQ: NETE), through its proposed merger with Mullen Technologies, is planning to divest its payments processing business model to enter the burgeoning EV industry. The strategic move will allow the stakeholders of privately held Mullen to gain a majority of the new stock while catalyzing the process of taking the company public and accelerating its expansion in the United States.

The bold move comes at a time of rapid industry expansion amid growing concern for the environment among the general public and policy-makers. Falling battery prices, government mandates and consumer incentives are propelling the industry forward, prompting some industry experts to predict that the pure electric models will surpass hybrids within the next few years as the transition takes place.

“I think we’ll see a faster transition to pure EVs,” said Dane Parker, an industry executive and participant at Business Insider’s IGNITION: Transportation virtual event (https://ibn.fm/cJ470). Besides his belief that hybrids are more complex to engineer, Parker predicts that by 2025 battery prices will have dropped substantially, resulting in the accelerated adoption of pure electric vehicles and their eventual dominance over hybrids.

Through its subsidiaries that include Mullen Auto Sales, Mullen Finance Corp., a digital marketplace called CarHub and battery-focused Mullen Energy, Mullen Technologies has already made significant headway in the US. Among the company’s expansion plans is the production of the Dragonfly K50 luxury electric sports car at its new proposed 1.3 million square-foot assembly and manufacturing space in Spokane, Washington. Featuring a Rechargeable Energy Storage System (RESS), the Dragonfly boasts a range of up to 310 miles and can accelerate from 0-60 miles/hour in under 4.2 seconds. Limited to only 1000 units, the company has started accepting reservations with production set to begin next year.

Pre-orders for another Mullen vehicle – the five-passenger MX-05 – have also begun. Production for the pure electric all-wheel SUV is set to begin in 2021 with deliveries set for mid-2022. Starting at $55,000, the MX-05 boasts a range of 325 miles on a single charge and can hit 60 miles/hour from zero in just 3.2 seconds.

Formerly a global financial technology and value-added solutions group, NETE plans to leverage the increased demand for electric vehicles through a proposed merger with Mullen Technologies. Based in California, Mullen Technologies engages in electric vehicle manufacturing across an international distribution network, partnering with several original equipment manufacturers across the world to provide exciting EV options for the US market.

For more information, visit the company’s website at www.NetElement.com.

NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

Monday, November 30th, 2020 Uncategorized Comments Off on $NETE As World Transitions away from Gas Guzzlers, Net Element Entering EV Market Through Mullen Technologies Merger

$GNPX Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is pleased to announce it has commenced clinical trial site recruitment for its upcoming Acclaim-1 clinical trial for the treatment of non-small cell lung cancer (NSCLC). As planned, the timing of the patient recruitment and enrollment puts the Company on track for its Acclaim-1 clinical trial to commence in the first-half of 2021.

Acclaim-1 is an open-label, multi-center Phase 1/2 clinical trial that combines Genprex’s lead drug candidate, REQORSA™ immunogene therapy with AstraZeneca PLC’s Tagrisso in patients with late stage NSCLC with mutated epidermal growth factor receptors (EGFRs), whose disease progressed after treatment with Tagrisso. Genprex received U.S. Food and Drug Administration (FDA) Fast Track Designation for its Acclaim-1 patient population in January of 2020.

“Our clinical team is engaging with prestigious cancer centers and research institutions across the U.S. to ensure we select optimal study sites, which play an important role in the success of a clinical trial,” said Rodney Varner, President and Chief Executive Officer of Genprex. “We look forward to working with leading clinical investigators who will help drive our mission to bring forth a treatment for advanced lung cancer patients.”

The Company plans to conduct the Acclaim-1 clinical trial in approximately 10 U.S. sites with about 100 patients (9-18 patients in the Phase 1 component and 82 patients in the Phase 2 component). An interim analysis will be performed after 53 events (i.e., progression of disease or death).

Additional information on the Acclaim-1 clinical trial can be found by visiting ClinicalTrials.gov .

About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA™ ( quaratusugene ozeplasmid ), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone .

For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on Twitter Facebook and LinkedIn .

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding the Company’s future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of REQORSA™ immunogene therapy drug, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including GPX-002, our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships, including those relating to manufacturing of our product candidates; the timing and success at all of obtaining FDA approval of REQORSA and our other potential product candidates including whether we receive or benefit from fast track or similar regulatory designations; costs associated with developing our product candidates, whether we identify and succeed in acquiring other technologies and whether patents will ever be issued under patent applications that are the subject of our license agreements or otherwise. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Genprex, Inc.
(877) 774-GNPX (4679)

Investor Relations
GNPX Investor Relations
(877) 774-GNPX (4679) ext. #2
investors@genprex.com

Media Contact
Genprex Media Relations
Kalyn Dabbs
(877) 774-GNPX (4679) ext. #3
media@genprex.com

Monday, November 30th, 2020 Uncategorized Comments Off on $GNPX Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

$AZRX Announces Advancement of MS1819 Combination Therapy Trial in Turkey

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that the first two patients have been dosed in Turkey for its Phase 2 trial. The trial evaluates its investigational drug, MS1819, in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (“PERT”), for the treatment of severe exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). “In the midst of a global pandemic and unpredictable obstacles, we are very encouraged to see our combination therapy trial moving forward at one of the clinical testing sites in Turkey,” said James Sapirstein, president & CEO of AzurRx. “We expect to release topline results in the second quarter of next year. We are optimistic the results will build on the encouraging data we received earlier this year and hope we will be one step closer to improving the lives of thousands of patients suffering from cystic fibrosis.”

To view the full press release, visit: https://ibn.fm/XGBwo

About AzurRx BioPharma Inc.

AzurRx BioPharma is a biopharmaceutical company specialized in the research and development of non-systemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial, and the Combination therapy trial, consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care. The company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at http://ibn.fm/AZRX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Monday, November 30th, 2020 Uncategorized Comments Off on $AZRX Announces Advancement of MS1819 Combination Therapy Trial in Turkey

CYBIN INC. (CYBN:AQL) Speakers at Harvard Law School Webinar Voice Support for Psychedelics Decriminalization

In a webinar hosted by the Petrie-Flom Center for Health Law Policy of the Harvard Law School, speakers championed for psychedelics decriminalization. The webinar, which gathered more than 200 individuals, had panelists who discussed the benefits of the decriminalization of psychedelics while debating on the history and safety of the substances and how they affected people of color.

The webinar’s moderator, Mason Marks, is a law professor at Gonzaga University. The speakers featured on the webinar included Patricia J. Zettler, associate professor at the Ohio State Moritz College of Law; Ifetayo Harvey, founder of the People of Color Psychedelic Collective; Dustin Marlan, assistant professor at the University of Massachusetts School of Law; and Larissa J. Maier, a postdoctoral scholar at the University of California San Francisco School of Pharmacy.

Marlan explained that individuals should be allowed to use psychedelics as long as their use does not affect or injure other individuals. Additionally, some speakers also advocated for the decriminalization of all drugs. Maier voiced her views on the issue, stating that no individual needed to be criminalized for the possession or use of a limited amount of drugs.

The speakers also traced drug prohibition in the United States back to the 1970s, asserting that prohibition efforts weren’t entrenched in drug-use prevention but in progressive social group disorganization. Harvey explained that the 1960s and 1970s had many movements, such as the anti-war movement and the civil rights movement, which explained the need to disrupt them.

According to the panelists, in addition to causing disruption these efforts also impeded research that may have revealed the possible uses of psychedelic substances in the medical field.

Maier explained that in the 1970s, more than 1,000 promising reports had been published that showed systematic reviews of the safety and effectiveness of LSD as a treatment for various mental health conditions.

Things are looking up though, after voters from the District of Columbia decriminalized psilocybin mushrooms and other psychedelic substances. In addition, the state of Oregon became the first state in the country to legalize psilocybin during the elections held three weeks ago.

Despite all panelists agreeing on the decriminalization of most drugs, some speakers expressed their concerns regarding such policies. Zettler and Harvey remarked that decriminalization could decrease drug use stigma but it could also foster a false sense of security for individuals who are not knowledgeable about laws concerning drug distribution and use.

Zettler added that it would be important to conduct research that looks into the effectiveness and safety of psychedelics before their use was legalized for the masses. This would help society understand the effects of these substances in detail.

The evolving regulatory landscape has allowed a number of companies to mushroom in the functional mushrooms space. For instance, Cybin Inc. (NEO: CYBN) is focused on developing fungi-based medications as well as functional wellness products.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Monday, November 30th, 2020 Uncategorized Comments Off on CYBIN INC. (CYBN:AQL) Speakers at Harvard Law School Webinar Voice Support for Psychedelics Decriminalization

Knightscope, Inc. Reimagines Public Safety Across the U.S. Through Autonomous Security Capabilities

  • Violent crimes in the U.S. occur every 24.6 seconds, and property crime occurs every 4.1 seconds
  • There are over 320 million people in the U.S., with only two million+ law enforcement and security professionals to protect them
  • Knightscope’s autonomous security robots are currently in operation across five U.S. time zones, with over one million hours in the field
  • The K1 is an award-winning ASR whose achievements were recognized with the 2018 Security Today New Product of the Year

Knightscope, a leader in the development of autonomous security capabilities, is reimagining public safety to make the United States the safest country in the world, through an innovative line of Autonomous Security Robot (“ASR”) products that combine self-driving technology, robotics, and artificial intelligence (https://ibn.fm/RLzlv).

In the United States, a violent crime occurs every 24.6 seconds and a property crime every 4.1 seconds, according to Knightscope statistics. Moreover, it is estimated that there are only a little over two million law enforcement and security officers across the country to help and protect a population of over 300 million people across all 50 states. Knightscope’s ASRs are helping to bridge the gap, offering valuable assistance and coverage and supporting law enforcement personnel to do their jobs more effectively.

The ASRs are typically used for patrolling and peacekeeping, as a means of physical deterrence by providing a visible, force multiplying, physical security presence to help protect assets and deter crime. However, they have also taken a more active role in fighting crime by assisting law enforcement and security with the arrests of suspects in crimes that range from armed robbery to hit-and-run accidents. More information about the work Knightscope is doing to fight crime is available at www.Knightscope.com/crime.

Knightscope’s current offering includes three ASR models being utilized across five time zones in the United States: K1, K3, and K5.

Recognized for its achievements with the 2018 Security Today New Product of the Year Award, K1 is a stationary machine that can be used in indoor or outdoor environments and is suitable for use in a wide range of spaces including parking structures, lobby and reception areas, high-risk areas, help or assistance points, transportation shuttle stops and more.

K3 is an indoor ASR that moves at speeds up to three miles per hour. It runs on its own 24/7/365 and can autonomously recharge itself without human intervention. It is the smart eyes and ears that cover many areas without the need for monotonous patrols. The K3 is suitable for environments such as malls, warehouses lobbies or offices, hospitals, airports, casinos, etc.

K5 is primarily used outdoors, even though it does have the capability of being used indoors. It features 24/7/365 operation and the ability to recharge autonomously without human intervention. This ASR model is best suited for large outdoor spaces and moves up to three miles per hour. The K5 has been operated for nearly one million hours in the field, including three winters. The K5 can be used in many large-spaced venues, including but not limited to hospitals, police departments, municipalities, airports, stadiums, manufacturing facilities, corporations and others.

All three of the ASR models feature the Knightscope Securities Operations Center (KSOC), which features force-multiplying physical deterrence, facial recognition, 360-degree HD video streaming, automatic license plate recognition, thermal anomaly detection, and so much more.

Knightscope has plans to develop other security solutions in the near future and is already in the process of raising additional growth capital while also preparing for a potential public listing. The company has already reserved the NASDAQ ticker symbol ‘KSCP’ and you can learn more reading the blog “Are You Going Public?!” (https://ibn.fm/78rrz). Since its foundation in 2013, Knightscope has raised more than $70 million to build all of its technology from scratch and is now backed by more than 16,000 investors and four major corporations.

For more information, visit the company’s website at www.Knightscope.com.

Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO.

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Wednesday, November 25th, 2020 Uncategorized Comments Off on Knightscope, Inc. Reimagines Public Safety Across the U.S. Through Autonomous Security Capabilities

Rritual Superfoods’ Extensive Distribution Network Set to Take Functional Mushrooms Mainstream

  • Functional Mushrooms Market Set for CAGR of 5.6%
  • Expected to Reach $24.85 billion by 2026
  • Rritual Superfoods Has Launched Three Mushroom-based Products
  • Products Boost Immune System, Brain Power and Relieve Stress
  • Company’s Extensive Distribution Network Set to Accelerate Sales

Consumers today shop for food with a number of considerations in mind, including food safety and the health benefits of their selected grocery items. This has resulted in increased demand for functional foods, with one sector — functional mushrooms — projected to increase at a CAGR of 5.6% during 2021–2026. This would put the market for functional mushrooms at $24.85 billion by the end of the forecast period. Rritual Superfoods is one of the companies operating in this nascent market.

Founded in 2019, Rritual has, to date, brought three mushroom-based products to market and is in the process of developing others. Rritual is working to ensure that its offerings not only augment the physical and psychological condition of consumers but also provide a healthy return for shareholders.

Functional foods, which are becoming increasingly popular, are foods that promote good health beyond the requirements of basic nutrition. Although the term “functional foods” may be relatively new, some traditional foods that fall into that category, such as oatmeal and orange juice fortified by calcium, are already staples in many diets.

Rritual is going a step beyond fortification. Rather than enhance the health benefits of food by adding nutrients, the company has developed its superfood offerings to be standalone supplements, which offers greater flexibility for consumers. With Rritual, consumers don’t need to consume more protein, carbohydrates or fats to receive the benefits.

Presently, Rritual Superfoods has three products derived from the chaga, lion’s mane, and reishi mushrooms. Rritual’s chaga blend boosts the immune system. Combined with the eleuthero root, the chaga-infused product, which also contains bioactive polysaccharides, increases resilience in the immune system and helps ward off infection.

The lion’s mane product is a brain booster. Its unique blend of lion’s mane mushroom and rhodiola root supports cognitive function and brain health, while also improving the body’s ability to cope with stress.

The reishi-based product also helps in dealing with stress. It includes the Ashwagandha root to help in combating anxiety and is rich in triterpenes, polysaccharides, fatty acids, and amino acids. Long-term use is said to improve the quality of sleep.

Rritual has devised a global sales and distribution strategy that covers three major markets: the United States, Canada, and Japan, through a growing network of online sales together with brick-and-mortar distribution.

For more information, visit the company’s website athttps://investors.wearerritual.com.

Mental Fitness Is A Daily Ritual.

NOTE TO INVESTORS: The latest news and updates relating to Rritual are available in the company’s newsroom at http://ibn.fm/Rritual

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Wednesday, November 25th, 2020 Uncategorized Comments Off on Rritual Superfoods’ Extensive Distribution Network Set to Take Functional Mushrooms Mainstream

As Global Cannabis Sales Grow 38% in 2020, Gage Cannabis Co. Expands to Offer Recreational Marijuana at Flagship Location

  • Research suggests cannabis sales increased 38% from 2019 to 2020
  • Gage expanding into fast-growing Michigan market, now offering recreational marijuana at flagship Ferndale location
  • Adult-use cannabis revenues in Michigan projected at $1 billion per year for 2021, surpassing $1.5 billion by 2023
  • Quarterly sales nearly doubled to $11.9 million in Q2 2020 from $5.8 million in Q1, expected to surpass $13.1 million in Q3

Recent research published by BDSA (formerly BDS Analytics) suggests that the global cannabis industry continues to grow despite COVID-19, with forecasts predicting that 2020 sales will reach $19.7 billion – an increase of 38% from 2019 (https://ibn.fm/EkGXb). One of Michigan’s fastest-growing cannabis brands, Gage Cannabis has expanded accordingly by offering recreational marijuana at its flagship Ferndale location. Gage is committed to building a solid reputation by providing top-tier cannabis experiences for the rapidly growing Michigan market.

“We have been looking forward to this day since we opened our doors in September 2019,” said Gage Cannabis President and Executive Vice President of Operations Mike Finos. “We are excited to extend the Gage experience to anyone aged 21 and over. Metro Detroit is home to our biggest consumers, and we’re ready to provide the community with quality products and a unique customer experience.”

Recreational use of cannabis in Michigan was first legalized in 2018, and the state has since emerged as one of the fastest-growing legal cannabis markets in the country in terms of consumption. Revenue projections by state budget planners suggest that the recreational marijuana market will be worth nearly $1 billion in fiscal 2021 with the potential to increase to $1.5 billion by 2023 (https://ibn.fm/wjWRx).

“Michigan is one of the top cannabis markets in the U.S., and I am confident Gage is poised to continue building on its historical execution and fortifying its position as one of the top operators and brands in Michigan, as well as a name consumers look for across the United States,” said Gage Cannabis Executive Chairman Bruce Linton (https://ibn.fm/LLQcw).

Gage produces its own in-house brands in addition to collaborating with several strategic partners and recognized names such as California-based Cookies – an iconic lifestyle brand widely known for its high-end cannabis strains and association with Berner, a rapper from the Bay Area. Sales bloomed during the COVID-19 lockdown period, nearly doubling to $11.9 million in Q2 from $5.8 million in Q1. The trend is expected to continue with management forecasting sales to surpass $13.1 million by the end of Q3 – an increase of over 150% from January to September 2020 (https://ibn.fm/W8INI). The company is currently planning to go public with a Canadian listing in early 2021 and has launched a Regulation A, Tier 2, equity financing.

To learn more about the company’s Regulation A financing, visit www.GageInvestors.com.

For more information, visit the company’s website at www.GageUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to Gage Cannabis are available in the company’s newsroom at https://ibn.fm/GAGE

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Wednesday, November 25th, 2020 Uncategorized Comments Off on As Global Cannabis Sales Grow 38% in 2020, Gage Cannabis Co. Expands to Offer Recreational Marijuana at Flagship Location

$MEDS Platform Meets Today’s Demands Through Intelligent Design

Trxade Group NASDAQ: MEDS), an integrated drug-procurement, delivery and health care platform, is ideally situated as the global pandemic has led to a cascade of changes involving how health care is administered, perhaps most notably in the increased adoption of telehealth services. Trxade Group’s business model appears to aptly and effectively meet today’s demands, largely demonstrated by the company’s revenue growth that has far exceeded expectations. A recent article discusses intelligent design of the Trxade platform that meets current standards of care while prioritizing information flow to assist both patients and providers. The article reads, “The company’s artificial intelligence API is designed to streamline the transfer of information between health care industry businesses. Trxade’s model thereby helps smaller, independent pharmacies in particular to competitively serve patients in spite of the proliferation of large pharmaceutical chains.”

To view the full article, visit: https://ibn.fm/CTgt8

About Trxade Group Inc.

Headquartered in Tampa, Florida, Trxade Group is an integrated drug-procurement, delivery and health care platform that fosters price transparency, thereby improving profit margins for both buyers and sellers of pharmaceuticals. Trxade Group operates across all 50 states with the central mission of making health care services affordable and accessible. Founded in 2010, Trxade Group is comprised of four synergistic operating platforms: (1) the Trxade B2B trading platform with 11,725 registered pharmacies; (2) Integra Pharma Solutions, Trxade Group’s virtual wholesale division; (3) the Bonum Health platform offering affordable telehealth services; and (4) the DelivMeds app, which coordinates a nationwide distribution network through independent pharmacies or mail-order delivery. For additional information, please visit www.Trxade.comwww.DelivMeds.com and www.BonumHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Wednesday, November 25th, 2020 Uncategorized Comments Off on $MEDS Platform Meets Today’s Demands Through Intelligent Design

$WTER 420 with CNW – Arkansas Governor Wants a More Aggressive Stance on Marijuana Legalization

Arkansas Gov. William Hutchinson states that the national government’s casual approach to cannabis is the reason why many more states are legalizing the drug. During a recent interview with the Washington Post, the governor of Arkansas explained that where the government’s stance on cannabis legalization is unclear, the legalization of drugs will continue, which brings about more measures for the legalization of cannabis at the state level.

Jeff Sessions, the first attorney general under outgoing President Donald Trump’s administration, revoked the counsel that was put in place by former President Barack Obama’s administration, which directed that state attorneys shouldn’t intrude on any state marijuana laws. However, apart from revoking former counsel, the Trump administration did not launch any extensive clamp down on people who complied with these local policies or the policies themselves.

Hutchinson explained that as long as the national government had a hands-off policy on all things marijuana in terms of legalization of marijuana in states, then the pressure for marijuana legalization will only grow. A lot of funds are used in that sector, which could result in additional initiatives to legalize the drug. Furthermore, increased funding poured into advertising these legalization initiatives and the lack of a clear position by the national government only furthers the cause. This is despite the fact that voters from Arkansas approved a measure on medical marijuana on their ballots in 2016.

This shouldn’t come as a surprise, given that the Hutchinson was the Drug Enforcement Administration head during the President George. W. Bush administration. The governor also mentioned that earlier this year, activists of reform from the state had tried placing an initiative that would legalize cannabis on the ballot of the state. However, they did not succeed as they were unable to gather the number of signatures needed to qualify for placement on the ballot because of the social-distancing measures implemented after the COVID-19 pandemic began. He added that while the activists had not been successful, they would try again.

Two decades ago, Hutchinson had the DEA raid various medical marijuana dispensaries in California, despite the fact that the dispensaries were legal. At the time, California was among the few states that had legalized medical cannabis.

When the governor was asked about the election victories seen in the states such as Oregon, which had legalized cannabis, he criticized the victories. It should be noted, however, that clinical studies have disproven many “reasons” that are cited by prohibitionists as reasons why cannabis should not be legalized.

The increase in the number of states with regulated cannabis markets has created a chance for many companies to grow. An example of such a company is The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER). WTER’s signature premium alkaline water as well as CBD-infused products can be found on the shelves of a minimum of 70,000 leading retail outlets around the United States.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Wednesday, November 25th, 2020 Uncategorized Comments Off on $WTER 420 with CNW – Arkansas Governor Wants a More Aggressive Stance on Marijuana Legalization

$SGTM Continues to Execute Expansion Strategy to Ensure Steady Growth

Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, continues to execute on its expansion strategy that combines organic growth, profitable acquisitions and strategic partnerships throughout the United States. The company, through its subsidiary Mulch Manufacturing Inc., has recently secured several new contracts to ensure steady growth. These include contracts to supply The Kroger Co. and Alimentation Couche-Tard Inc. – specifically, for multiple divisions of its Circle K subsidiary. “Securing a mulch and soil purchasing agreement with the Louisville, Kentucky division of The Kroger Company is an honor and the first step to expand further into their other divisions,” SGTM CEO and Director Tony Raynor said of one partnership, further discussing multiple contract awards. “Obtaining Circle K mulch contracts for 2021 gives us an amazing opportunity to build a relationship with their brand and expand throughout more stores. We have been blessed to be offered these amazing opportunities from large chain accounts to help further expand our brand and overall exposure.”

To view the full article, visit https://ibn.fm/57Eti

About Sustainable Green Team Ltd.

Sustainable Green Team, through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris, which has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The company’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting tree debris through its tree services division and collection sites and then, through its processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic-growth and strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified. The company’s customers include governmental, residential and commercial clients.

For additional information regarding SGTM’s operations, expansion plans and production facilities, view the company’s presentation. For more information about the company’s Mulch Manufacturing subsidiary, visit www.MulchMfg.com.

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Wednesday, November 25th, 2020 Uncategorized Comments Off on $SGTM Continues to Execute Expansion Strategy to Ensure Steady Growth

$POAI Skyline Medical Sells 15 Streamway(R) Systems in Q3 2020 as COVID-era Drives Need for Sanitation Systems

  • Closed design of Streamway(R) System provides safety from potential hazards of drips and spills during endoscopy, radiology, cystoscopy, urology procedures
  • The Streamway(R) System reduces costs, minimizes environmental impact of 50 million potentially disease-infected canisters disposed into landfills
  • POAI’s Skyline Medical sells 8 Streamway(R) Systems to large university hospital in Virginia, 15 sold halfway into Q3 2020

In the age of COVID-19, the need for sanitation and safety during hospital procedures has reached an all-time high. Health professionals have reported an inhibited level of performance due to a lack of protection, comfort, and increased fatigue during surgery (https://ibn.fm/87UEr). Sanitary disposal systems, able to offer maximum protection to healthcare workers, have become incredibly necessary—and companies like Predictive Oncology are answering the call. Produced by Skyline Medical, a subsidiary of Predictive Oncology (NASDAQ: POAI), the patented Streamway(R) System features an entirely closed design, ensuring that medical professionals are safe from the potential hazards of drips and spills. It’s the first FDA-cleared direct-to-drain fluid disposal system that is designed specifically for medical applications such as endoscopy, radiology, cystoscopy and urology procedures.

The proprietary system automates the collection, measurement and disposal of potentially infectious waste that includes blood and irrigation fluids. By connecting directly to a facility’s plumbing system, the Streamway(R) System has the potential to change the way healthcare facilities manage fluid disposal by minimizing human intervention and increasing compliance with Occupational Safety and Health Administration (“OSHA”) and other regulatory agency safety guidelines.

Along with addressing safety concerns, the use of the Streamway(R) System reduces costs and minimizes environmental impacts by eliminating carts, evacuated bottles and the approximately 50 million potentially disease-infected canisters that go into landfills each year in the United States. COVID-era concerns have increased sales of the Streamway(R) System in 2020, with 15 sales in Q3 (including eight to a large university hospital organization in Virginia) in addition to sales throughout the world through direct sales and distributor partners.

Along with Skyline, POAI leverages the synergies of its other three wholly-owned subsidiaries – Helomics, TumorGenesis, and Soluble Biotech – to fulfill its mission of bringing precision medicine to the diagnosis of cancer. Besides the Streamway(R) System, POAI’s portfolio assets also include an AI-enhanced “smart” patient-derived tumor profiling platform, an in-house bioinformatics artificial intelligence (AI) platform, and a data-based approach to growing patient-specific tumors in a lab for the development of personalized treatment options.

The importance of precision medicine in cancer therapeutics has grown substantially, driven specifically by data-based predictive models of tumors and their responses to pharmaceutical treatments. Modeling various tumors can be both time and data-intensive, requiring five to seven years of clinical evaluation and observation to produce both historical and outcome data.

To that end, POAI has a significant competitive advantage through its vast collection of tumors and their related data, in addition to the company’s ability to access associated outcome data. The application of AI to its trove of more than 150,000 tumors assists oncologists in providing individualized patient treatments while driving forward the development of new targeted therapies in collaborations with pharmaceutical companies.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Wednesday, November 25th, 2020 Uncategorized Comments Off on $POAI Skyline Medical Sells 15 Streamway(R) Systems in Q3 2020 as COVID-era Drives Need for Sanitation Systems

$DRIO to Provide Digital Therapeutics Solution to Employees of Fortune 500 Company

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, will be providing its digital therapeutics solution to qualified employees of a U.S.-based Fortune 500 technology company. The contract, which goes into effect on Jan. 1, 2021, with the beginning of a new benefits year, calls for Dario to provide its digital diabetes tools and coaching to employees and their dependents. “We believe that employees will benefit from Dario’s unique therapeutic approach, which delivers adaptive, personalized experiences designed to drive behavior change through intuitive, clinically proven digital tools and coaching,” said DarioHealth president and North America GM Rick Anderson in the press release. “These employees will join a community of tens of thousands of members who engage with Dario every day to measurably improve their health. This contract was awarded through a request for proposal (“RFP”) process that included Dario’s largest competitors, and we believe it represents an important milestone in our strategic shift toward the business-to-business-to-consumer (“B2B2C”) market comprised of self-insured employers, healthcare provider networks, and insurance plans. We believe this further validates the competitive strength of our top-rated digital chronic care solution and will serve as an important market reference in converting our employer pipeline.”

To view the full press release, visit: https://ibn.fm/ddd7y

About DarioHealth Corp.

DarioHealth Corp. is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, the company empowers individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Dario’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. For more information about the company, please visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Wednesday, November 25th, 2020 Uncategorized Comments Off on $DRIO to Provide Digital Therapeutics Solution to Employees of Fortune 500 Company

$CNSP IND Application for Cancer Drug Berubicin Accepted for Review

  • CNS Pharmaceuticals wants to obtain FDA authorization for an Investigational New Drug application for drug candidate Berubicin, a novel treatment for Glioblastoma Multiforme
  • Company believes it’s on track to start in Q1 2021 a potentially pivotal Phase II Berubicin trial with adult GBM patients who have failed their primary treatment for the disease
  • Separately, a Phase II adult trial and a first-ever Phase I pediatric trial are slated to begin in 2021 in Poland in collaboration with sub-licensee partner, WPD Pharmaceuticals
  • Members of CNS’s management team attended A.G.P.’s Virtual Health Symposium, meeting 1-on-1 with investors

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, recently announced that it has filed an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for its lead drug candidate Berubicin. This application has been accepted for review (https://ibn.fm/6NnwH).

Berubicin is proposed for the treatment of Glioblastoma Multiforme (“GBM”), an aggressive form of brain cancer currently considered incurable, and may prove beneficial in treating other central nervous system malignancies. Since gaining the rights to Berubicin, and securing from Reata Pharmaceuticals, Inc. (NASDAQ: RETA) the Phase 1 trial data and assets, CNS has worked diligently to complete the requirements to bring the drug to trial.

John Climaco, CEO of CNS Pharmaceuticals, Inc., made a statement about the IND filing and how the tireless efforts of the team during the last year have helped reach this important milestone. “Our laser focus from the beginning has been to start the next phase of the investigation of Berubicin for the treatment of this deadly disease as quickly as possible,” he added.

The company believes it is well positioned to execute its plan and initiate a potentially pivotal Phase II trial for Berubicin in Q1 2021 beginning in the United States and expanding to a global trial. The Phase II Berubicin trial that is currently planned in Q1 2021 will evaluate the efficacy of Berubicin in patients with GBM who have failed primary treatment for the disease. Results will be compared with the current second-line standard of care. The trial will be executed with a 2 to 1 randomization of the participating 243 patients to Berubicin or Lomustine (as standard of care). This trial could potentially provide data to the FDA needed for approval of an expedited pathway for further development or approval.

CNS Phamaceuticals, in collaboration with sublicensee partner WPD Pharmaceuticals (CSE: WBIO) (FSE: 8SV1), is preparing two other clinical trials for Berubicin in Poland. The two studies include a Phase II trial in adults (set to begin in February 2021) and the first-ever Phase I trial for pediatric patients (scheduled to start later in 2021) (https://ibn.fm/p1zJ8).

The IND announcement came a few days before CNS management members attended A.G.P.’s Virtual Healthcare Symposium that took place Thursday, November 19, 2020. The virtual event brought together numerous healthcare and biotech companies for one-on-one meetings with investors, engaging panels and discussions with leading healthcare executives and a keynote speaker address (https://ibn.fm/jNkR6).

The IND filing and the upcoming clinical trials make Berubicin an interesting opportunity for investors, as CNS believes its novel treatment can fill the current gap in available GBM treatments and help position the company as a market leader in this fast-growing sector. The overall global brain tumor therapeutics market is targeted to reach an estimated $3.4 billion by 2025, from $2.25 billion in 2019, reflecting a CAGR of 7.20% during the forecast period of 2019 to 2025, Market Study Report research shows (https://ibn.fm/SQkrD). Another report estimated that this market would reach $2.74 billion in 2023, registering a CAGR of 11% during the forecast period of 2018 to 2023 (https://ibn.fm/EnB3Q).

For more information, visit the company’s website at www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Wednesday, November 25th, 2020 Uncategorized Comments Off on $CNSP IND Application for Cancer Drug Berubicin Accepted for Review

$AZRX Planning to Test Immediate Release MS1819 Capsules in Cystic Fibrosis Study

  • The company plans to add another study arm to its ongoing Phase 2b OPTION 2 clinical study which currently tests delayed release capsules
  • If it receives FDA approval, AzurRx would be able to identify the optimal delivery method for its drug candidate MS1819 without significant extra costs or delays
  • Enrollment in this arm of the study could begin as early as December 2020

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, has submitted a protocol amendment request to the U.S. Food and Drug Administration that would allow it to test immediate release capsules of its exocrine pancreatic insufficiency drug candidate MS1819.

According to a company press release, if the amendment is approved, AzurRx would modify its current Phase 2b OPTION 2 trial of MS1819 in cystic fibrosis patients to add a study arm that uses immediate release capsules (https://ibn.fm/Ws66z). The existing arm of the study uses delayed release capsules. This would allow AzurRx to compare data from both arms to determine the best delivery method for its lead product.

“As this trial progresses, we believe there may be significant clinical value in adding a study arm that uses our immediate release capsules. Our intention is to identify the optimal delivery method and potentially provide additional scientific support and optionality for MS1819,” AzurRx Chief Medical Officer Dr. James Pennington said.

The addition of a new arm would not impact the overall trial objectives, endpoints and statistical analysis of the Phase 2b OPTION 2 trial. “We are pleased to announce that our OPTION 2 trial is well ahead of schedule and almost fully enrolled without any safety issues being observed,” Dr. Pennington added. He also explained that determining appropriate dosage and delivery method is an important goal for any Phase 2 clinical trial, along with testing for safety and efficacy, before entering a Phase 3 program. He added that if the amendment is accepted by the FDA, AzurRx expects to begin enrollment into the new study arm as soon as December 2020.

AzurRx CEO James Sapirstein also said that the protocol amendment is a unique opportunity for the company to acquire valuable additional clinical data with no significant delays in the study timeline and no significant increase in overall costs.

The Phase 2b OPTION 2 trial consists of testing MS1819 doses in enteric capsule form with two concentrations: 2240mg and 4480mg. Initial results from the study indicated that the MS1819 non-porcine recombinant lipase is well tolerated at both dose levels and produces no adverse effects.

AzurRx is also conducting a Phase 2 cystic fibrosis combination trial, using MS1819 together with porcine pancreatic enzyme replacement therapy (“PERT”), the current standard of care. This study uses daily PERT doses in combination with different MS1819 dosages (700mg, 1120mg and 2240mg) and results made available so far have shown clinically meaningful improvements in subjects, with no adverse safety events.

According to Sapirstein, the company remains on target to release to line data for its Phase 2b trial in the first quarter of 2021. Top line data for the combination trial is expected in the second quarter.

Pending the Phase 2b trial outcome, the company will initiate a Phase 3 trial in cystic fibrosis and to this end, it has already identified and signed a binding letter of intent with a potential partner for the development and production of MS1819 for the study. Under the agreement, Asymchem, a leading global contract development and manufacturing service provider, will implement fermentation, verify protein expression, and fine-tune the technology for MS1819 production to help AzurRx optimize manufacturing and prepare for commercialization (https://ibn.fm/HJwT4).

AzurRx is determined to develop MS1819 as a safer alternative to porcine pancreatic enzyme replacement therapy, significantly reducing the pill burden of cystic fibrosis patients. The company believes that due to its safety and efficacy, its proposed therapy has the potential to improve the quality of life and help achieve healthier nutrition for many patients suffering from severe exocrine pancreatic insufficiency, including those with cystic fibrosis, chronic pancreatitis, pancreatectomy, and other indications.

For additional information, visit www.AzurRx.com or contact the following:
AzurRx BioPharma, Inc.
Phone: (646) 699-7855
info@azurrx.com

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Wednesday, November 25th, 2020 Uncategorized Comments Off on $AZRX Planning to Test Immediate Release MS1819 Capsules in Cystic Fibrosis Study

$AZRX Microorganisms Found in Child’s Bed Dust May Boost Their Health

In collaboration with the Gentofte Hospital and the Danish Pediatric Asthma Center, University of Copenhagen researchers from the Department of Biology have discovered a connection between children’s bacteria and the microorganisms that exist in the beds of children in an extensive study.

This link implies that the microorganisms may decrease the risk of a child developing autoimmune diseases, allergies and asthma as they grow. While these microorganisms are invisible to the naked eye, they exist in multitudes in a child’s bed, influencing the development of microorganisms in children’s bodies. Ultimately, this impacts how resistant children become to different diseases.

To understand the link better, the researchers examined dust samples that were collected from the beds of 577 children. They then compared these samples to the respiratory samples gathered from 542 infants. The study’s objective was to find out if there was a connection between the bacteria discovered in the infant’s respiratory tracts and the dust microorganisms as well as the environmental factors that influenced microorganism composition in the dust from the infant’s beds.

Professor Søren J. Sørensen explained that researchers found a link between the two bacteria found in children and in the bed dust samples, thus suggesting that the bacteria do influence each other. As we all know microorganisms that live in us are important, especially for one’s health with respect to allergies and asthma, for instance. This also applies to diseases such as obesity and type 2 diabetes.

Sørensen says that to improve how these ailments are treated, the processes through which microbial life turn up in the early stages of a child’s development needs to be better understood. The microbial life in a bed is influenced by its surroundings. Therefore, changing one’s bedsheets repeatedly may not be required, if further research proves the claim to be right.

Additionally, the researchers studied urban and rural dwellings. They collected 930 fungi and bacteria types from the beds of six-month-old infants. They discovered that rural dwellings had much higher bacteria levels when compared with urban homes. Sørensen explained that prior research has shown that people living in rural areas have more diverse gut flora than city-dwellers. This is mainly because they have more contact with nature and spend a majority of their time outdoors.

Living in rural areas and having pets or older siblings adds to a reduced risk of developing any autoimmune ailments.

Many companies are striving to help patients with gastrointestinal complaints access better treatment. A notable entity in this regard is AzurRx BioPharma Inc. (NASDAQ: AZRX). MS1819, one of AzurRx’s latest drug candidates, is poised to reduce how many pills patients suffering from cystic fibrosis need to take.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Wednesday, November 25th, 2020 Uncategorized Comments Off on $AZRX Microorganisms Found in Child’s Bed Dust May Boost Their Health

Cybin Inc. (NEO: CYBN) Canadian Government Gives Formal Response to Petition to Decriminalize Psychedelics

Officials of the federal government of Canada have given an official response to a petition that called for psychedelic decriminalization in the country. The statement highlighted that there were various ways for some individuals to obtain exemptions to consume the substances legally, despite the drugs being illegal for the Canadian majority.

Government ministers stated that the psychedelic substances had to be studied more before any reforms were made. The petition, which garnered almost 15,000 signatures, was launched on the House of Commons’ site earlier this summer. The appeal requested legislators to decriminalize entheogenic fungi and plants to be used in various therapeutic practices, including healing ceremonies, as well as medical care.

Typically petitions have a 500-signature threshold, so by getting almost 30 times the number of signatures required, this proposal qualified to be presented to Parliament, with the government required to respond within 45 days. The petition was also read before the House of Commons on Sept. 30, 2020. The formal response from the government was announced last week.

The petition also calls for the government to respect the cultural and historical traditions around psychedelics. This would be done by the discontinuation of the enforcement of regulations or statutes that ban or impose heavy restrictions on adult use as well as the sharing or growing of any fungi or plant, particularly with regard to traditional use.

Ministers of Public Safety and Emergency Preparedness, Health and Justice all issued statements. Despite two of the statements admitting that there are opportunities for solitary exemptions under the CDSA for specific types of drug use, all statements re-emphasize that the trafficking and possession as well as the manufacture of psychedelic substances are still illegal acts.

Psychedelic substances are required to be approved by Canada’s drug review process and be authorized by Health Canada before they can be used as a mainstream therapeutic.

David Lametti, the attorney general, stated that the law provided the Minister of Health with the power to grant exemptions from the Controlled Drugs and Substances Act for scientific, medical and other public interest purposes. The latter included the protection of fundamental freedoms, such as the freedom of peaceful assembly, expression and religion. Lametti added that the extensive decriminalization petition wouldn’t comply with Canada’s agreement with international drug conventions, which include the Psychotropic Substances UN Convention 1971.

There is hope, however. In September, Patty Hajdu, Canadian health minister, gave four cancer patients an exemption that would allow them to have their end-of-life care include the use of psychedelic mushrooms.

The psychedelic and functional mushrooms sector in Canada is witnessing a growth spurt. Cybin Inc. (NEO: CYBN) is one of the key players in this industry, and its management team, which has an impressive list of clinical studies under their belt, is poised to make the company a leader in the psychedelic medicines and related products space.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Wednesday, November 25th, 2020 Uncategorized Comments Off on Cybin Inc. (NEO: CYBN) Canadian Government Gives Formal Response to Petition to Decriminalize Psychedelics

$MEDS Are Shares of $CVS Still a Buy After the Launch of Amazon Pharmacy?

The public health crisis has accelerated CVS Health’s (CVS) transformation from a pharmacy and retailer into a health insurance and healthcare supplier. Its recent decline due to the launch of Amazon Pharmacy, could be a buying opportunity.

CVS Health Corporation (CVS) is a healthcare service provider in the United States, operating through three segments – Pharmacy Services, Retail/LTC, and Health Care Benefits. As the novel coronavirus continues to spread across the United States, CVS has rolled out thousands of COVID-19 test sites and launched a new business-to-business testing program for corporations and colleges. The company also provided home delivery of OTC and prescription drugs during the social distancing restrictions through CVS Pharmacy.

Last week Amazon launched its new pharmacy business, which will compete with CVS in selling prescription drugs.  As a result, CVS’s stock plunged, but since then has recouped some of its losses.

To compete with Amazon, the company will need to continue to concentrate on digitizing its operations. The company’s positive returns over the past six months combined with several other factors have helped it earn a “Buy” rating in our proprietary rating system.

Here’s how our proprietary POWR Ratings system evaluates CVS:

Trade Grade: A

CVS is currently trading above its 50-day and 200-day moving averages of $60.72 and $62.46, respectively, indicating that the stock is in an uptrend. The stock gained 4.2%, over the past three months, reflecting short-term bullishness.

CVS’s revenue increased 3.5% year-to-date to $67.06 billion in the third quarter ended September 2020. Operating income grew 11% from the year-ago value to $3.62 billion, while the pharmacy segment’s gross profit rose 10.7% to $1.90 billion in the third quarter.

CVS recently announced the expansion of its COVID-19 testing services. It plans to add nearly 1000 testing sites by the end of this year. Since March, the company has undertaken more than 5 million coronavirus tests.

The retail division of CVS recently launched QuickRenew, an at-home contact lens prescription renewal tool, that allows users to renew their prescriptions online.

Buy & Hold Grade: B

In terms of proximity to its 52-week high, which is a key factor that our Buy & Hold Grade takes into account, CVS is well-positioned. The stock is currently trading just 13.3% below its 52-week high of $77.03.

The company’s net revenue grew at a CAGR of 13.3% over the past three years, while net income increased at a CAGR of 16.4% over this period. Also, EPS increased at a CAGR of 7.6% over the past three years.

This can be attributed to the company’s long-term strategic plan of transforming health care and innovative solutions in tandem with the evolving economy to meet customer needs.

Peer Grade: B

CVS is currently ranked #1 out of 4 stocks in the Medical – Drug Stores group. Other popular stocks in this industry are Walgreens Boots Alliance, Inc. (WBA), Rite Aid Corporation (RAD), and Trxade Group, Inc. (MEDS).

WBA, RAD, and MEDS declined 4.1%, 12.1% and 11.7%, respectively, over the past six months. This compares to CVS’s 5.4% return over this period.

Industry Rank: B

The Medical – Drug Stores industry is ranked #34 out of the 123 StockNews.com industries. The companies in this industry sell health products, prescription drugs, general merchandise from physical retail locations and over-the-counter medications.

The pandemic has revealed the limitations of the global healthcare system, and is inducing governments to take immediate action to transform the same. Initially, the industry experienced restrained growth as lockdowns disrupted the global supply chain and logistics. However, the market for medical supplies is expected to grow due to the increased requirement of PPE kits & N95 masks globally, the rising demand for ventilators, and the increasing need for diagnostic supplies. Also, CVS plans to roll out Covid-19 vaccines globally when those are ready to hit the market.

Overall POWR Rating: B (Buy)

CVS is rated “Buy” due to its impressive financials, short-and-long-term bullishness, and underlying industry strength, as determined by the four components of our overall POWR Rating.

Bottom Line

Healthcare demand is expected to grow due to the ongoing coronavirus pandemic and CVS can still thrive, even with the launch of Amazon Pharmacy.

Analyst sentiment, which gives a good sense of a stock’s future price movement, is pretty impressive for CVS. It has an average broker rating of 1.31, indicating favorable analyst sentiment. Out of 25 Wall Street analysts that rated the stock, 19 rates it a “Strong Buy”. The consensus EPS estimate of $0.43 for the current year indicates a 4.9% improvement year-over-year. CVS has an impressive earnings surprise history, with the company beating consensus EPS estimates in each of the trailing four quarters. The consensus revenue estimate of $267.88 billion for the current year indicates a 4.3% increase from the same period last year.

 


CVS shares were trading at $68.38 per share on Tuesday afternoon, up to $1.60 (+2.40%). Year-to-date, CVS has declined -5.03%, versus a 14.46% rise in the benchmark S&P 500 index during the same period.


Tuesday, November 24th, 2020 Uncategorized Comments Off on $MEDS Are Shares of $CVS Still a Buy After the Launch of Amazon Pharmacy?